[1]
|
Bibby AC, Tsim S, Kanellakis N, et al. Malignant pleural mesothelioma: an update on investigation, diagnosis and treatment[J]. Eur Respir Rev, 2016, 25: 472-486. |
[2]
|
Sekido Y. Molecular pathogenesis of malignant mesothelioma[J]. Carcinogenesis, 2013, 34: 1413-1419. |
[3]
|
刘均平, 杨力, 郭新宁.胸腹膜恶性间皮瘤一例[J].中华消化杂志, 2000, 20: 260. |
[4]
|
刘艳群, 王开绿, 郑晓凤, 等.胸腹膜恶性间皮瘤1例并文献复习[J].临床肺科杂志, 2006, 11: 738. |
[5]
|
李娜, 轩菡, 陈婷婷.恶性胸膜间皮瘤伴腹膜广泛病变1例报告[J].安徽医学, 2014, 35: 707-708. |
[6]
|
Jiang X, Hidru TH, Zhang Z, et al.Evidence of elemene injection combined radiotherapy in lung cancer treatment among patients with brain metastases: A systematic review and meta-analysis[J]. Medicine (Baltimore), 2017, 96: e6963. |
[7]
|
Henderson DW, Reid G, Kao SC, et al. Challenges and controversies in the diagnosis of mesothelioma: Part 1. Cytology-only diagnosis, biopsies, immunohistochemistry, discrimina-tion between mesothelioma and reactive mesothelial hyperplasia, and biomarkers[J]. J Clin Pathol, 2013, 66: 847-853. |
[8]
|
Arif Q, Husain AN. Malignant Mesothelioma Diagnosis[J]. Arch Pathol Lab Med, 2015, 139: 978-980. |
[9]
|
刘标, 周晓军.恶性间皮瘤的病理诊断[J].诊断病理学杂志, 2014, 21: 1-3. |
[10]
|
Vogelzang NJ, Rusthoven JJ, Symanowski J, et al. Phase Ⅲ study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma[J]. J Clin Oncol, 2003, 21:2636-2644. https://academic.oup.com/jjco/article/38/5/339/805437 |
[11]
|
Van Meerbeeck JP, Gaafar R, Manegold C, et al. Randomized phase Ⅲ study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada[J]. J Clin Oncol, 2005, 23:6881-6889. https://www.ncbi.nlm.nih.gov/pubmed/16192580 |
[12]
|
Zalcman G, Mazieres J, Margery J, et al. Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial[J]. Lancet, 2016, 387:1405-1414. https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(15)01238-6/fulltext |